ANCO’s ASCO Highlights 2019
ANCO's ASCO Update on HR+ Breast Cancer - Increased OS with Ribociclib/Endocrine Therapy & Improved PFS with Capivasertib + Fulvestrant
By
ANCO’s ASCO Highlights 2019
FEATURING
Helen K. Chew
By
ANCO’s ASCO Highlights 2019
FEATURING
Helen K. Chew
Comments 0
Login to view comments.
Click here to Login
